Literature DB >> 1718800

CD5+ B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects.

D A Schatz1, F Lang, A B Cantor, W J Riley, N K Maclaren, J W Sleasman, D J Barrett.   

Abstract

Human CD5+ B lymphocytes produce autoantibodies that bind to self- and exogenous antigens. Extremely high percentages of CD5+ B lymphocytes are present in the fetal and newborn periods, whereas they constitute only a minority of B lymphocytes in healthy adults. Increased percentages of circulating CD5+ lymphocytes have previously been demonstrated in several autoimmune diseases, including rheumatoid arthritis, progressive systemic sclerosis, Graves' disease, and Sjögren's syndrome. We measured the percentages of B lymphocytes that expressed the CD5 determinant in 93 control subjects (age range 1 day to 59 yr, mean +/- 22.6 +/- 17.7 yr), 17 subjects with newly diagnosed insulin-dependent diabetes mellitus (IDDM; range 5-29 yr, mean +/- SD 13 +/- 5.9 yr), 31 high-risk islet cell antibody (ICA)-positive nondiabetic subjects (range 4-45 yr, mean +/- SD 19.8 +/- 14.1 yr), and 13 subjects with IDDM of greater than 5 yr duration (range 10-43 yr, mean +/- SD 24.2 +/- 9.9 yr). We report that CD5+ B-lymphocyte percentages are strikingly age dependent in healthy control subjects, declining progressively from the newborn period to the middle-age years (r = -0.75, P = 0.0001). In ICA+ nondiabetic and recent-onset IDDM subjects less than 29 yr of age, the percentage of circulating CD5+ B lymphocytes fell within the 95% confidence intervals established for control subjects. However, the age-dependent rate of decline in the percentage of CD5+ B lymphocytes within the control range was slower in ICA+ and newly diagnosed IDDM subjects than in control subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718800     DOI: 10.2337/diab.40.10.1314

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  4 in total

1.  Hiding in plain sight: time to unlock autoimmune clues in human CD5+ B cells by using nextgen technology.

Authors:  Rizwan Ahmed; Zahra Omidian; Thomas Donner; Abdel Rahiam A Hamad
Journal:  Discov Med       Date:  2018-09       Impact factor: 2.970

2.  NOD mice are defective in proteasome production and activation of NF-kappaB.

Authors:  T Hayashi; D Faustman
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

3.  Anti-islet cell and anti-insulin antibody production by CD5+ and CD5- B lymphocytes in IDDM.

Authors:  A Muñoz; T Gallart; E F Usac; J Fernández-Alvarez; O Viñas; N Somoza; J Barceló; R Gomis
Journal:  Diabetologia       Date:  1995-01       Impact factor: 10.122

4.  Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients.

Authors:  Ankit Saxena; Hideo Yagita; Thomas W Donner; Abdel Rahim A Hamad
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.